Dyne Therapeutics receives "Buy" rating from 10 analysts with a $50.60 price target, despite reporting Q2 EPS of -$0.70.
Dyne Therapeutics, a clinical-stage biotechnology firm focused on muscle diseases, has received an average "Buy" rating from ten analysts, with a 12-month price target of $50.60. The company reported a Q2 earnings per share of -$0.70, surpassing expectations. Institutional ownership is high at 96.68%, with significant investment activity noted. Recent upgrades in price targets from various analysts reflect positive sentiment about the company's prospects.
September 01, 2024
5 Articles